Genmab — April 2025
-
Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
New data show early hints of the medicine improving patient survival — the gold standard outcome of any cancer study
STAT (www.statnews.com)
-
Her kom svaret https://finance.yahoo.com/news/interim-overall-survival-analysis-requested-185000973.html Hazard ration på OS stiger fra første interim analyse på 0,51 til 0,78 i anden interim analyse.
-
https://investors.biontech.de/news-releases/news-release-details/biontech-acquire-biotheus-boost-oncology-strategy/ De lavede et køb i 2024 på det nævnte stof VEGF-A/PD-L1 på $800 mln.
-
Tepezza (teprotumumab) received a positive opinion from the CHMP for the treatment of adults with moderate to severe Thyroid Eye Disease (TED), also known as Graves’ Eye Disease, a rare autoimmune disease that triggers inflammation of muscles, fat, and other tissues around and behind the eyes. Treatment options for moderate-to-severe TED are limited, most patients are treated with corticosteroids and some patients need multiple reconstructive surgeries
-
Rina-S Displays Early Efficacy in Advanced Ovarian Cancer https://www.onclive.com/view/rina-s-displays-early-efficacy-in-advanced-ovarian-cancer
-
JNJ.N - Q1 2025 Johnson & Johnson Earnings Call TRANSCRIPT https://s203.q4cdn.com/636242992/files/doc_downloads/2025/04/JNJ_N-Transcript-2025-04-15T12_30.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind